A Family of Synergistic
Technology Solutions

Precigen is focused on improving patient care through innovative gene and cell therapies. Our subsidiaries are an important part of realizing this mission as they are advancing a portfolio of unique solutions to address unmet needs in health.

Pioneering a new class of microbe-based pharmaceutical agents through its ActoBiotics™ platform for expression and local delivery of therapeutics at disease sites including the intestine, the mouth and the nasopharynx to treat a range of disorders

Discover More

Enabling discovery by providing porcine research models and services that aid scientists in the understanding of human disease mechanisms, development of new therapeutics, development of next-generation medical procedures and devices, and optimization of novel diagnostics

Discover More

Advancing targeted, controllable, and multigenic gene therapies designed to address multiple aspects of underlying pathologies for the treatment of complex cardiovascular diseases

Discover More

Precigen’s healthcare assets include wholly-owned subsidiaries PGEN Therapeutics, Precigen ActoBio and Precigen Exemplar, and a majority ownership interest in Precigen Triple-Gene.

While our primary focus is in healthcare, Precigen controls two non-healthcare businesses: an established bovine genetics company, Trans Ova Genetics, and an industry-leading methane bioconversion business, MBP Titan, LLC.